Everything tagged "growth" across research, earnings, and macro.
192 articles
Cerebras got sold like demand had cracked, but the latest quarter said the opposite. With 92% core revenue growth and major OpenAI and AWS validation, CBRS looks like a margin scare that the market may have overpunished.
Micron has evolved from a cyclical memory name into a higher-quality AI infrastructure supplier with record profitability, strong customer commitments, and rising visibility. The report supports a Buy as HBM demand, richer mix, and tighter supply drive earnings power.
Arista Networks is emerging as a key AI infrastructure beneficiary, with Q1 2026 revenue up 35.1% and management lifting its full-year outlook. The stock looks like a premium compounder, but valuation remains the main debate.
Arm is posting 20%+ annual growth as royalty strength and AI data center demand accelerate, but the stock still trades at a demanding valuation. The business quality is excellent, yet the shares look more attractive on pullbacks than at current levels.
Booking Holdings combines elite cash generation, rising merchant mix, and global travel scale, but near-term growth is slowing after Middle East disruption. The stock looks like a disciplined Buy for medium-term investors rather than a momentum chase.
Summit Therapeutics is a high-risk, high-upside oncology story built around ivonescimab, with positive Phase III data and an FDA review underway. The stock looks attractive for investors willing to accept binary regulatory risk in exchange for platform-scale potential.
Astera Labs is turning AI infrastructure demand into rapid revenue and profit growth, but the stock’s valuation remains stretched. The business is strong, the balance sheet is clean, and the shares already discount a lot of future success.
Intuitive Surgical continues to compound through rising procedures, a larger installed base, and an increasingly recurring revenue mix. The main debate is whether that quality justifies the stock’s premium valuation.
GE Vernova is emerging as a major beneficiary of global electrification, with record backlog, surging orders, and raised 2026 guidance. Wind remains a drag, but Power and Electrification are driving margin expansion and cash flow.
Marvell is emerging as a major AI infrastructure beneficiary, with data center revenue now 76% of sales and management guiding for roughly 40% growth in fiscal 2027. The stock still screens expensive, so the upside depends on execution across interconnect, switching, and custom silicon.
CrowdStrike is still posting elite growth, with record ARR, strong free cash flow, and raised guidance. But the stock’s premium valuation leaves less room for error, making it a quality Hold rather than an obvious buy.
O’Reilly Automotive continues to post strong comp growth, margin resilience, and share gains, but the stock’s premium valuation keeps the debate centered on price rather than business quality.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the Generator